TransMedics GroupTMDX +3.44%69 EBIT per Share is $2.67 as of Mar. 2026. GuruFocus rates TMDX with a GF Score™ of 69/100 and a GF Value™ of $167.91 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 690 Medical Devices & Instruments companies, TransMedics Group ranks worse than 144927.39% on this metric.
TransMedics Group's EBIT per Share for the
three
months ended in Mar. 2026 was $0.43.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.67.
During the past 12 months, the average EBIT per Share Growth Rate of TransMedics Group was 69.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for TransMedics Group's EBIT per Share or its related term are showing as below:
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of TransMedics Group was 20.10% per year. The lowest was -10.80% per year. And the median was 6.10% per year.
TMDX's 3-Year EBIT Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.5 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
TransMedics Group (NAS:TMDX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
TransMedics Group EBIT per Share Related Terms
TransMedics Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for TransMedics Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.67
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransMedics Group (TMDX) has a EBIT per Share of $2.67 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on TransMedics Group and its competitors. According to the industry distribution chart, TransMedics Group ranks #999999 out of 690 companies in the Medical Devices & Instruments industry.
Is TransMedics Group's EBIT per Share too high?
TransMedics Group's current EBIT per Share is $2.67. The Medical Devices & Instruments industry median EBIT per Share is 9.50. TransMedics Group's value of $2.67 is 71.9% below this industry median. Based on the distribution chart, TransMedics Group ranks #999999 out of 690 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TransMedics Group has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's EBIT per Share compare to AXGN and BFLY?
According to the Medical Devices & Instruments industry distribution chart, TransMedics Group ranks #999999 out of 690 companies for EBIT per Share. This places TransMedics Group in the lower half of its industry. The industry median EBIT per Share is 9.50. TransMedics Group's value of $2.67 is 71.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransMedics Group's current EBIT per Share of $2.67 is 71.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on TransMedics Group and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransMedics Group's current EBIT per Share is $2.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
Based on GuruFocus' analysis, TransMedics Group (TMDX) is currently considered Possible Value Trap. The stock's GF Value™ is $167.91, compared to a current price of $71.23 — trading 57.6% below its estimated fair value. The current EBIT per Share is $2.67 and 71.9% below the Medical Devices & Instruments industry median of 9.50. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For TransMedics Group (TMDX), the current EBIT per Share is $2.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TransMedics Group (TMDX) Overvalued in 2026?
Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued.
The current stock price of $71.23 is trading 57.6% below its estimated GF Value™ of $167.91.
GuruFocus considers TransMedics Group to be Possible Value Trap.
Key valuation signals for TMDX:
EBIT per Share: $2.67
GF Value™: $167.91 vs. price of $71.23 (57.6% below fair value)
Industry Position: 71.9% below the Medical Devices & Instruments median (#999999 of 690)
No single metric tells the full story. See the TMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score
Get the complete analysis for TMDX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMDX has been successfully added to your 
